伊顿制药
ETON
50.31
-1.02
-1.99%
伊顿制药
US · ETON
#2944 按市值排名
上市于 2018
50.31
-1.02
-1.99%
实时 - 追踪5344个代码 - 心跳于320秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了5家。
- 机构持股总比例下降了2.9个百分点。
机构持股
- 机构持股比例
- 68.96% -2.90pp
- 机构数量
- 191 +5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund30.53%
Mutual Fund29.61%
Public Company4.92%
Individual/Insider4.90%
Private Company1.95%
Insurance Company0.91%
Sovereign Wealth Fund0.60%
Government Pension Fund0.35%
Other26.14%
主要股东 截至 2026-07-14
Opaleye Management Inc.
9.46% · 2.71M 股
EcoR1 Capital, LLC
7.60% · 2.17M 股
BlackRock
6.63% · 1.90M 股
Nantahala Capital Management, LLC
4.11% · 1.18M 股
Vanguard Capital Management, LLC
4.01% · 1.15M 股
Sean Brynjelsen
3.36% · 961.19K 股
Morgan Stanley
2.63% · 751.03K 股
State Street Global Advisors
2.46% · 701.79K 股
Geode Capital Management, LLC
2.28% · 652.30K 股
Oberweis Asset Management, Inc.
1.75% · 501.60K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 28次买入 · 17次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Sean Brynjelsen | Chief Executive Officer | 3.36% |
| Norbert Riedel | Independent Chairperson | 0.78% |
| Paul Maier | Independent Director | 0.25% |
| Charles Casamento | Independent Director | 0.24% |
| David Krempa | Chief Business Officer | 0.13% |
| Danka Radosavljevic | Senior Vice President of Quality & Operations | 0.08% |
| James Gruber | Chief Financial Officer | 0.06% |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer | 0.00% |
| Opaleye Management Inc. | -- | -- |
| Jennifer Adams | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-27 | Paul Maier | Independent Director | Derivative Exercise and Sale | -50,000 | $3.78–61.77 |
| 2026-08-27 | Paul Maier | Independent Director | Other Derivative Acquisition | +12,500 | $7.31 |
| 2026-08-27 | Paul Maier | Independent Director | Derivative Exercise and Retained | +12,500 | $7.31 |
| 2026-08-23 | David Krempa | Chief Business Officer | Derivative Exercise and Sale | -25,000 | $7.31–65.07 |
| 2026-08-19 | Sean Brynjelsen | Chief Executive Officer | Open Market Disposition | -100,000 | $60.17–62.65 |
| 2026-08-18 | Sean Brynjelsen | Chief Executive Officer | Intent to Sell (Form 144) | -100,000 | $63.43 |
| 2026-07-30 | Paul Maier | Independent Director | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | Charles Casamento | Independent Director | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | Norbert Riedel | Independent Chairperson | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | David Krempa | Chief Business Officer | Other Derivative Acquisition | +128,985 | -- |
| 2026-07-30 | Jennifer Adams | Independent Director | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | Judith Matthews | Executive Vice President of Accounting & Finance | Other Derivative Acquisition | +32,246 | -- |
| 2026-07-30 | Danka Radosavljevic | Senior Vice President of Quality & Operations | Initial Statement of Beneficial | 0 | -- |
| 2026-07-30 | Ipek Erdogan-Trinkaus | Chief Commercial Officer | Other Derivative Acquisition | +80,000 | -- |
| 2026-07-13 | Opaleye Management Inc. | -- | Open Market Disposition | -28,315 | $37.54 |
| 2026-07-13 | Sean Brynjelsen | Chief Executive Officer | Derivative Exercise and Retained | +227,500 | $1.37 |
| 2026-07-13 | Sean Brynjelsen | Chief Executive Officer | Other Derivative Acquisition | +200,000 | $1.37 |
| 2026-07-11 | David Krempa | Chief Business Officer | Derivative Exercise and Retained | +10,000 | -- |
| 2026-07-06 | Opaleye Management Inc. | -- | Open Market Disposition | -126,685 | $37.39–38.37 |
| 2026-06-25 | David Krempa | Chief Business Officer | Other Derivative Acquisition | +10,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:06 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
伊顿制药 讨论区 0 条评论